MA33536B1 - Anticorps monoclonaux anti-cea humanisés obtenus par maturation d'affinité - Google Patents
Anticorps monoclonaux anti-cea humanisés obtenus par maturation d'affinitéInfo
- Publication number
- MA33536B1 MA33536B1 MA34650A MA34650A MA33536B1 MA 33536 B1 MA33536 B1 MA 33536B1 MA 34650 A MA34650 A MA 34650A MA 34650 A MA34650 A MA 34650A MA 33536 B1 MA33536 B1 MA 33536B1
- Authority
- MA
- Morocco
- Prior art keywords
- abms
- relates
- nucleic acid
- millennium
- maturation
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3007—Carcino-embryonic Antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Oncology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Cette invention concerne des molécules se liant à l'antigène (ABM). Dans des modes de réalisation particuliers, cette invention concerne des anticorps monoclonaux recombinés, comprenant des anticorps chimériques, primatisés ou humanisés ou des variants de ceux-ci spécifiques des antigènes CEA humains liés à la surface des cellules ou à la membrane. De plus, cette invention concerne des molécules d'acides nucléiques codant pour ces ABM, et des vecteurs et des cellules hôtes comprenant lesdites molécules d'acides nucléiques. Cette invention concerne, en outre, des procédés de production d'ABM selon l'invention, et des méthodes d'utilisation de ces ABM pour traiter des maladies. Des ABM à glycosylation modifiée ayant des propriétés thérapeutiques améliorées, comprenant des anticorps présentant une liaison accrue aux récepteurs Fc et une fonction effectrice accrue sont également décrites.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US23850509P | 2009-08-31 | 2009-08-31 | |
PCT/EP2010/062527 WO2011023787A1 (fr) | 2009-08-31 | 2010-08-27 | Anticorps monoclonaux anti-cea humanisés obtenus par maturation d'affinité |
Publications (1)
Publication Number | Publication Date |
---|---|
MA33536B1 true MA33536B1 (fr) | 2012-08-01 |
Family
ID=42985489
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA34650A MA33536B1 (fr) | 2009-08-31 | 2012-02-27 | Anticorps monoclonaux anti-cea humanisés obtenus par maturation d'affinité |
Country Status (23)
Country | Link |
---|---|
US (2) | US9068008B2 (fr) |
EP (1) | EP2473532B1 (fr) |
JP (1) | JP5744872B2 (fr) |
KR (1) | KR101528013B1 (fr) |
CN (1) | CN102741293B (fr) |
AR (1) | AR078111A1 (fr) |
AU (1) | AU2010288469A1 (fr) |
BR (1) | BR112012003983A2 (fr) |
CA (1) | CA2770174A1 (fr) |
CL (1) | CL2012000551A1 (fr) |
CO (1) | CO6491105A2 (fr) |
CR (1) | CR20120087A (fr) |
EC (1) | ECSP12011698A (fr) |
HK (1) | HK1176951A1 (fr) |
IL (1) | IL218038A0 (fr) |
MA (1) | MA33536B1 (fr) |
MX (1) | MX339608B (fr) |
PE (1) | PE20121552A1 (fr) |
RU (1) | RU2570554C2 (fr) |
SG (1) | SG178567A1 (fr) |
TW (1) | TW201121994A (fr) |
WO (1) | WO2011023787A1 (fr) |
ZA (1) | ZA201200954B (fr) |
Families Citing this family (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5992710A (ja) * | 1982-11-16 | 1984-05-29 | 関西電力株式会社 | 直接水冷線路の立坑部の布設方法 |
NZ603111A (en) | 2001-08-03 | 2014-05-30 | Roche Glycart Ag | Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity |
KR20130118941A (ko) | 2011-02-10 | 2013-10-30 | 로슈 글리카트 아게 | 면역치료법 |
PL3489255T3 (pl) | 2011-02-10 | 2021-11-22 | Roche Glycart Ag | Zmutowane polipeptydy interleukiny-2 |
PL2681244T3 (pl) * | 2011-03-02 | 2018-04-30 | Roche Glycart Ag | Przeciwciała przeciwko antygenowi rakowo-płodowemu |
EA201892619A1 (ru) * | 2011-04-29 | 2019-04-30 | Роше Гликарт Аг | Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2 |
HUE038225T2 (hu) | 2011-08-23 | 2018-10-29 | Roche Glycart Ag | Bispecifikus, T-sejtaktiváló antigénkötõ, molekulák |
MX349095B (es) | 2011-08-23 | 2017-07-11 | Roche Glycart Ag | Moleculas biespecificas de union a antigeno. |
CA2844540C (fr) | 2011-08-23 | 2018-10-16 | Roche Glycart Ag | Anticorps bispecifiques specifiques pour les antigenes d'activation des lymphocytes t et un antigene tumoral et procedes d'utiliation correspondants |
WO2013054320A1 (fr) | 2011-10-11 | 2013-04-18 | Tel Hashomer Medical Research Infrastructure And Services Ltd. | Anticorps dirigés contre la molécule d'adhésion cellulaire associée à l'antigène carcino-embryonnaire (ceacam) |
GB201213858D0 (en) | 2012-08-03 | 2012-09-19 | Mab Design Ltd | Method |
JP6290209B2 (ja) | 2012-08-07 | 2018-03-07 | ロシュ グリクアート アーゲー | 低下した及び増加したエフェクター機能を有するように操作された2つの抗体を含む組成物。 |
KR20150064068A (ko) | 2012-10-08 | 2015-06-10 | 로슈 글리카트 아게 | 2개의 Fab 단편을 포함하는 FC-부재 항체 및 이용 방법 |
CN110845618A (zh) | 2013-02-26 | 2020-02-28 | 罗切格利卡特公司 | 双特异性t细胞活化抗原结合分子 |
MX2015010843A (es) * | 2013-02-26 | 2016-04-04 | Roche Glycart Ag | Moleculas biespecificas de union al antigeno que activan celulas t. |
SG11201504497TA (en) | 2013-02-26 | 2015-09-29 | Roche Glycart Ag | Bispecific t cell activating antigen binding molecules |
US11427647B2 (en) | 2014-04-27 | 2022-08-30 | Famewave Ltd. | Polynucleotides encoding humanized antibodies against CEACAM1 |
AU2015254886A1 (en) | 2014-04-27 | 2016-11-03 | Ccam Biotherapeutics Ltd. | Humanized antibodies against CEACAM1 |
LT3177643T (lt) | 2014-08-04 | 2019-08-12 | F. Hoffmann-La Roche Ag | T ląstelę aktyvinantį antigeną surišančios bispecifinės molekulės |
BR112017010324A2 (pt) | 2014-11-20 | 2018-05-15 | F. Hoffmann-La Roche Ag | método para tratar ou retardar a progressão de um câncer em um indivíduo, moléculas, métodos para aumentar a função imune em um indivíduo e para selecionar um paciente para tratamento, kits, composição farmacêutica e usos de uma combinação de uma molécula |
AR106188A1 (es) | 2015-10-01 | 2017-12-20 | Hoffmann La Roche | Anticuerpos anti-cd19 humano humanizados y métodos de utilización |
MA43025A (fr) | 2015-10-02 | 2021-05-26 | Hoffmann La Roche | Molécules bispécifiques de liaison à l'antigène activant les lymphocytes t anti-ceaxcd3 |
WO2017097723A2 (fr) | 2015-12-09 | 2017-06-15 | F. Hoffmann-La Roche Ag | Méthode de traitement |
AU2017205089B2 (en) | 2016-01-08 | 2023-10-05 | F. Hoffmann-La Roche Ag | Methods of treating CEA-positive cancers using PD-1 axis binding antagonists and anti-CEA/anti-CD3 bispecific antibodies |
DK3433280T3 (da) | 2016-03-22 | 2023-06-19 | Hoffmann La Roche | Protease-aktiverede T-celle-bispecifikke molekyler |
CN107663240B (zh) | 2016-07-29 | 2021-01-12 | 中国人民解放军第四军医大学 | 高度糖基化cea特异性结合的单链抗体及其在检测和治疗上的应用 |
ES2897217T3 (es) | 2016-09-30 | 2022-02-28 | Hoffmann La Roche | Anticuerpos biespecíficos frente a p95HER2 |
CR20200391A (es) | 2018-02-08 | 2020-10-19 | Genentech Inc | Moléculas biespecíficas de unión al antígeno y métodos de uso |
JP2022539344A (ja) * | 2019-06-26 | 2022-09-08 | 江蘇恒瑞医薬股▲ふん▼有限公司 | 抗cea抗体及びその応用 |
MX2021015888A (es) | 2019-06-26 | 2022-03-22 | Hoffmann La Roche | Fusión de un anticuerpo que se une a cea y 4-1bbl. |
CN110713539B (zh) * | 2019-09-23 | 2021-04-16 | 华道(上海)生物医药有限公司 | 一种抗癌胚抗原的抗体及其制备方法和用途 |
CN110862456B (zh) * | 2019-09-23 | 2021-04-09 | 华道(上海)生物医药有限公司 | 一种抗癌胚抗原的抗体及其制备方法和用途 |
IL298402A (en) | 2020-06-19 | 2023-01-01 | Hoffmann La Roche | Antibodies that bind to CD3 and CD19 |
EP4100028A4 (fr) | 2020-08-20 | 2023-07-26 | A2 Biotherapeutics, Inc. | Compositions et méthodes de traitement de cancers positifs à la mésothéline |
CA3188867A1 (fr) | 2020-08-20 | 2022-02-24 | Xueyin Wang | Compositions et methodes de traitement de cancers positifs a ceacam |
WO2023147426A2 (fr) * | 2022-01-27 | 2023-08-03 | Janssen Biotech, Inc. | Compositions de protéines améliorées |
WO2023180489A1 (fr) | 2022-03-23 | 2023-09-28 | Synaffix B.V. | Anticorps-conjugués pour le ciblage de tumeurs exprimant un antigène carcinoembryonnaire |
Family Cites Families (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
ES2165851T3 (es) | 1991-11-25 | 2002-04-01 | Enzon Inc | Proteinas multivalentes que se unen a antigenos. |
US5872215A (en) | 1991-12-02 | 1999-02-16 | Medical Research Council | Specific binding members, materials and methods |
AU672951B2 (en) * | 1992-05-07 | 1996-10-24 | Ge Healthcare As | Complexing agents and targeting immunoreagents |
GB9317423D0 (en) * | 1993-08-21 | 1993-10-06 | Imp Cancer Res Tech | Monoclonal antibodies |
GB9324807D0 (en) | 1993-12-03 | 1994-01-19 | Cancer Res Campaign Tech | Tumour antibody |
US6001358A (en) | 1995-11-07 | 1999-12-14 | Idec Pharmaceuticals Corporation | Humanized antibodies to human gp39, compositions containing thereof |
US6417337B1 (en) * | 1996-10-31 | 2002-07-09 | The Dow Chemical Company | High affinity humanized anti-CEA monoclonal antibodies |
AU3657899A (en) * | 1998-04-20 | 1999-11-08 | James E. Bailey | Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity |
US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
EP2264166B1 (fr) | 1999-04-09 | 2016-03-23 | Kyowa Hakko Kirin Co., Ltd. | Methode de regulation de l'activite d'une molecule immunologiquement fonctionnelle |
CN101676400A (zh) | 2000-07-31 | 2010-03-24 | 比洛克西治疗公司 | 在浮萍中表达生物活性多肽 |
US6946292B2 (en) | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
US6815175B2 (en) * | 2001-03-16 | 2004-11-09 | Cornell Research Foundation, Inc. | Anti-amyloid peptide antibody based diagnosis and treatment of a neurological disease or disorder |
US7321026B2 (en) | 2001-06-27 | 2008-01-22 | Skytech Technology Limited | Framework-patched immunoglobulins |
NZ603111A (en) | 2001-08-03 | 2014-05-30 | Roche Glycart Ag | Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity |
DE60232265D1 (de) | 2001-10-25 | 2009-06-18 | Genentech Inc | Glycoprotein-zusammensetzungen |
US20040093621A1 (en) | 2001-12-25 | 2004-05-13 | Kyowa Hakko Kogyo Co., Ltd | Antibody composition which specifically binds to CD20 |
NZ533868A (en) | 2001-12-27 | 2008-09-26 | Glycofi Inc | Methods to engineer mammalian-type carbohydrate structures |
US7432063B2 (en) | 2002-02-14 | 2008-10-07 | Kalobios Pharmaceuticals, Inc. | Methods for affinity maturation |
US20040132101A1 (en) | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
US20070148171A1 (en) * | 2002-09-27 | 2007-06-28 | Xencor, Inc. | Optimized anti-CD30 antibodies |
EP2319935B1 (fr) | 2002-03-19 | 2016-04-27 | Stichting Dienst Landbouwkundig Onderzoek | Expression de GnTIII (UDP-N-acétylglucosamine: Beta -D mannoside Beta (1,4)-N-acétylglucosaminyltransferase III) dans des plantes |
JP4628679B2 (ja) | 2002-04-09 | 2011-02-09 | 協和発酵キリン株式会社 | Gdp−フコースの輸送に関与する蛋白質の活性が低下または欠失した細胞 |
EA200401325A1 (ru) | 2002-04-09 | 2005-04-28 | Киова Хакко Когио Ко., Лтд. | Клетки с модифицированным геномом |
CA2481837A1 (fr) | 2002-04-09 | 2003-10-16 | Kyowa Hakko Kogyo Co., Ltd. | Procede de production de composition anticorps |
US20050031613A1 (en) * | 2002-04-09 | 2005-02-10 | Kazuyasu Nakamura | Therapeutic agent for patients having human FcgammaRIIIa |
EP1498491A4 (fr) * | 2002-04-09 | 2006-12-13 | Kyowa Hakko Kogyo Kk | Procede d'amelioration de l'activite d'une composition d'anticorps de liaison avec le recepteur fc gamma iiia |
US7232888B2 (en) | 2002-07-01 | 2007-06-19 | Massachusetts Institute Of Technology | Antibodies against tumor surface antigens |
WO2004013180A2 (fr) * | 2002-08-01 | 2004-02-12 | Immunomedics, Inc. | Anticorps anti-alpha-fetoproteine immu31, proteines de fusion et procedes d'utilisation de ceux-ci |
PT1539966E (pt) | 2002-09-12 | 2010-09-14 | Greenovation Biotech Gmbh | Método de produção de proteínas |
WO2004057002A2 (fr) | 2002-12-20 | 2004-07-08 | Greenovation Biotech Gmbh | Ameliorations apportees ou associees a la production de proteines |
AU2004204494B2 (en) | 2003-01-09 | 2011-09-29 | Macrogenics, Inc. | Identification and engineering of antibodies with variant Fc regions and methods of using same |
JP5425365B2 (ja) | 2003-01-22 | 2014-02-26 | グリカート バイオテクノロジー アクチェンゲゼルシャフト | 増加したFcレセプター結合親和性およびエフェクター機能を有する抗体を作製するための融合構築物およびその使用 |
CA2525120C (fr) * | 2003-05-14 | 2013-04-30 | Domantis Limited | Procede de recuperation de polypeptides qui se deplient de facon reversible a partir d'un repertoire de polypeptides |
PL2681244T3 (pl) * | 2011-03-02 | 2018-04-30 | Roche Glycart Ag | Przeciwciała przeciwko antygenowi rakowo-płodowemu |
-
2010
- 2010-08-27 MX MX2012002461A patent/MX339608B/es active IP Right Grant
- 2010-08-27 CA CA2770174A patent/CA2770174A1/fr not_active Abandoned
- 2010-08-27 BR BR112012003983-0A patent/BR112012003983A2/pt not_active Application Discontinuation
- 2010-08-27 WO PCT/EP2010/062527 patent/WO2011023787A1/fr active Application Filing
- 2010-08-27 SG SG2012013306A patent/SG178567A1/en unknown
- 2010-08-27 JP JP2012526072A patent/JP5744872B2/ja not_active Expired - Fee Related
- 2010-08-27 RU RU2012112340/10A patent/RU2570554C2/ru active
- 2010-08-27 AU AU2010288469A patent/AU2010288469A1/en not_active Abandoned
- 2010-08-27 EP EP10745651.9A patent/EP2473532B1/fr active Active
- 2010-08-27 PE PE2012000266A patent/PE20121552A1/es not_active Application Discontinuation
- 2010-08-27 KR KR1020127008265A patent/KR101528013B1/ko active IP Right Grant
- 2010-08-27 CN CN201080048622.1A patent/CN102741293B/zh not_active Expired - Fee Related
- 2010-08-30 AR ARP100103166A patent/AR078111A1/es not_active Application Discontinuation
- 2010-08-30 TW TW099129130A patent/TW201121994A/zh unknown
- 2010-08-31 US US12/872,908 patent/US9068008B2/en active Active
-
2012
- 2012-01-30 CO CO12014021A patent/CO6491105A2/es not_active Application Discontinuation
- 2012-02-08 ZA ZA2012/00954A patent/ZA201200954B/en unknown
- 2012-02-09 IL IL218038A patent/IL218038A0/en unknown
- 2012-02-20 CR CR20120087A patent/CR20120087A/es unknown
- 2012-02-27 MA MA34650A patent/MA33536B1/fr unknown
- 2012-02-28 EC ECSP12011698 patent/ECSP12011698A/es unknown
- 2012-02-29 CL CL2012000551A patent/CL2012000551A1/es unknown
-
2013
- 2013-04-15 HK HK13104510.8A patent/HK1176951A1/xx not_active IP Right Cessation
-
2015
- 2015-05-26 US US14/721,795 patent/US20160075795A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
AU2010288469A1 (en) | 2012-03-01 |
ECSP12011698A (es) | 2012-03-30 |
CL2012000551A1 (es) | 2012-10-12 |
EP2473532A1 (fr) | 2012-07-11 |
MX2012002461A (es) | 2012-03-14 |
US9068008B2 (en) | 2015-06-30 |
JP2013502913A (ja) | 2013-01-31 |
TW201121994A (en) | 2011-07-01 |
US20160075795A1 (en) | 2016-03-17 |
AR078111A1 (es) | 2011-10-12 |
CR20120087A (es) | 2012-03-22 |
PE20121552A1 (es) | 2012-11-26 |
IL218038A0 (en) | 2012-04-30 |
JP5744872B2 (ja) | 2015-07-08 |
KR101528013B1 (ko) | 2015-06-16 |
WO2011023787A1 (fr) | 2011-03-03 |
EP2473532B1 (fr) | 2017-06-21 |
CN102741293B (zh) | 2015-04-01 |
RU2570554C2 (ru) | 2015-12-10 |
CN102741293A (zh) | 2012-10-17 |
HK1176951A1 (en) | 2013-08-09 |
MX339608B (es) | 2016-05-31 |
US20110104148A1 (en) | 2011-05-05 |
ZA201200954B (en) | 2014-07-30 |
RU2012112340A (ru) | 2013-10-10 |
CO6491105A2 (es) | 2012-07-31 |
SG178567A1 (en) | 2012-04-27 |
BR112012003983A2 (pt) | 2021-09-14 |
KR20120060874A (ko) | 2012-06-12 |
CA2770174A1 (fr) | 2011-03-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA33536B1 (fr) | Anticorps monoclonaux anti-cea humanisés obtenus par maturation d'affinité | |
ECSP21023271A (es) | Anticuerpos cd20 con función del efector y afinidad de enlace al receptor fc mejoradas | |
TW200720439A (en) | Antigen binding molecules directed to mcsp and having increased fc receptor binding affinity and effector function | |
TW200639181A (en) | Antigen binding molecules that bind EGFR, vectors encoding same, and uses thereof | |
WO2008017963A3 (fr) | Molécules de liaison à l'antigène se liant au récepteur du facteur de croissance épidermique, vecteurs codant pour de telles molécules, et leurs utilisations | |
AR055137A1 (es) | Moleculas de union al antigeno modificadas con actividad de senalizacion celular alterada | |
CR8389A (es) | Anticuerpos cd20 con funcion del efector y afinidad de enlace al receptor fc mejoradas |